Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oculis Holding (OCS)
NASDAQ:OCS
Holding OCS?
Track your performance easily
OCS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.60 - $18.00
Previous Close$14.91
Volume45.13K
Average Volume (3M)48.48K
Market Cap
$627.01M
Enterprise Value$523.86M
Total Cash (Recent Filing)CHF91.65M
Total Debt (Recent Filing)CHF605.00K
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Mar 24, 2025EPS Estimate
-$0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding41,750,000
10 Day Avg. Volume48,017
30 Day Avg. Volume48,480
Standard Deviation0.16
R-Squared0.00106
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)6.66
Price to Sales (P/S)599.98
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$29.67Price Target Upside101.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Oculis Holding News
PremiumCompany Announcements
Oculis Holding AG Reports Q3 2024 Financial Progress
PremiumCompany Announcements
Oculis Holding’s Financial Struggles Amid Asset Growth
PremiumCompany Announcements
Oculis Holding Shows Strong Asset and Equity Growth
Bulls Say, Bears Say
Bulls Say
Cash Runway ExtensionManagement has carried out financing deals to extend the cash runway of the company.
FDA ConfirmationThe FDA has confirmed that the completed Phase 3 OPTIMIZE-1 trial, the completed Phase 2 SKYGGN trial, and the safety data from completed trials in ocular surgery and diabetic macular edema (DME) are sufficient to support an NDA submission.
Orphan Drug DesignationOCS-05 has been granted Orphan Drug designation in the U.S. and Europe.
Bears Say
EfficacyThe durability of Restoret's efficacy is not clear at this time.
Market UseRestoret may be primarily used in patients who have already exhibited suboptimal response to anti-VEGFs if and when it reaches the market.
Program OddsThe small size of patient sub-group limits ability to increase program odds-of-success.
---
Ownership Overview
―
Insiders
0.04% Mutual Funds
5.10% Other Institutional Investors
94.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
OCS FAQ
What was Oculis Holding’s price range in the past 12 months?
Oculis Holding lowest stock price was $9.60 and its highest was $18.00 in the past 12 months.
What is Oculis Holding’s market cap?
Currently, no data Available
When is Oculis Holding’s upcoming earnings report date?
Oculis Holding’s upcoming earnings report date is Mar 24, 2025 which is in 122 days.
How were Oculis Holding’s earnings last quarter?
Oculis Holding released its earnings results on Nov 07, 2024. The company reported -$0.544 earnings per share for the quarter, missing the consensus estimate of -$0.534 by -$0.01.
Is Oculis Holding overvalued?
According to Wall Street analysts Oculis Holding’s price is currently Undervalued.
Does Oculis Holding pay dividends?
Oculis Holding does not currently pay dividends.
What is Oculis Holding’s EPS estimate?
Oculis Holding’s EPS estimate is -$0.49.
How many shares outstanding does Oculis Holding have?
Oculis Holding has 41,745,296 shares outstanding.
What happened to Oculis Holding’s price movement after its last earnings report?
Oculis Holding reported an EPS of -$0.544 in its last earnings report, missing expectations of -$0.534. Following the earnings report the stock price went down -0.533%.
Which hedge fund is a major shareholder of Oculis Holding?
Among the largest hedge funds holding Oculis Holding’s share is Saba Capital Management. It holds Oculis Holding’s shares valued at N/A.
---
Oculis Holding Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.67 (101.15% Upside)
$29.67 (101.15% Upside)
Hedge Fund Trend
Decreased
By 663.6K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.15%
12-Months-Change
Fundamentals
Return on Equity
-69.05%
Trailing 12-Months
Asset Growth
5.64%
Trailing 12-Months
Company Description
Oculis Holding
European Biotech Acquisition Corp is a blank check company.
---
OCS Stock 12 Month Forecast
Average Price Target
$29.67
▲(101.15% Upside)
Technical Analysis
Best Analysts Covering OCS
1 Year
1 Year Success Rate
7/9 ratings generated profit
1 Year Average Return
+16.79%
reiterated a buy rating 3 months ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +16.79% per trade.
---